$SLXN
Silexion Therapeutics Corp

2024 Q3 Form 10-Q Financial Statement

#000121390024073934 Filed on August 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2024 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $262.1K
YoY Change -40.42%
% of Gross Profit
Research & Development $3.217M $766.0K
YoY Change 501.31% -37.98%
% of Gross Profit
Depreciation & Amortization $22.00K $7.000K
YoY Change 120.0% -50.0%
% of Gross Profit
Operating Expenses $8.036M $1.385M $274.2K
YoY Change 4922.5% -2.05% -37.69%
Operating Profit -$8.036M -$1.385M
YoY Change 999.32% -2.05%
Interest Expense $73.93K
YoY Change -90.14%
% of Operating Profit
Other Income/Expense, Net $3.822M $102.0K
YoY Change 5208.33% -77.43%
Pretax Income -$11.86M -$1.487M -$200.2K
YoY Change -17040.0% -20.31% -164.59%
Income Tax $2.000K $2.000K
% Of Pretax Income
Net Earnings -$11.86M -$1.489M -$200.2K
YoY Change -17042.86% -20.63% -164.59%
Net Earnings / Revenue
Basic Earnings Per Share $2.03 $5.87
Diluted Earnings Per Share $2.03 $5.87 -$0.05
COMMON SHARES
Basic Shares Outstanding 9.768M shares 250.8K shares
Diluted Shares Outstanding 5.828M shares 250.8K shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.815M
YoY Change -78.38%
Cash & Equivalents $1.973M $1.697M $2.831M
Short-Term Investments $5.810M
Other Short-Term Assets $80.00K $66.00K $26.90K
YoY Change
Inventory
Prepaid Expenses $944.0K $527.0K
Receivables
Other Receivables
Total Short-Term Assets $3.047M $2.315M $5.842M
YoY Change -46.54% -91.58% -78.36%
LONG-TERM ASSETS
Property, Plant & Equipment $35.00K $40.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $40.00K $210.0K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.047M $2.315M $5.842M
Total Long-Term Assets $40.00K $210.0K $0.00
Total Assets $3.087M $2.525M $5.842M
YoY Change -45.84% -90.82% -78.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $799.0K $281.0K
YoY Change 181.0%
Accrued Expenses $56.80K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.583M $2.364M $3.193M
YoY Change 43.32% 7.45% 68.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $4.083M $8.000K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.583M $2.364M $3.193M
Total Long-Term Liabilities $4.083M $8.000K $0.00
Total Liabilities $7.666M $2.372M $3.193M
YoY Change 206.64% 3.13% 68.07%
SHAREHOLDERS EQUITY
Retained Earnings -$41.58M -$29.66M
YoY Change
Common Stock $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.579M -$18.26M $2.649M
YoY Change
Total Liabilities & Shareholders Equity $3.087M $2.525M $5.842M
YoY Change -45.84% -90.82% -78.36%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$11.86M -$1.489M -$200.2K
YoY Change -17042.86% -20.63% -164.59%
Depreciation, Depletion And Amortization $22.00K $7.000K
YoY Change 120.0% -50.0%
Cash From Operating Activities -$2.653M -$1.065M -$265.6K
YoY Change 8743.33% -36.46% -150.11%
INVESTING ACTIVITIES
Capital Expenditures $16.00K
YoY Change 166.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$16.00K
YoY Change -122.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $2.920M 275.0K
YoY Change -113.41% -100.3%
NET CHANGE
Cash From Operating Activities -$2.653M -$1.065M -265.6K
Cash From Investing Activities -$16.00K
Cash From Financing Activities $2.920M 275.0K
Net Change In Cash $251.0K -$1.065M 9.430K
YoY Change -101.15% -7.87% -100.01%
FREE CASH FLOW
Cash From Operating Activities -$2.653M -$1.065M -$265.6K
Capital Expenditures $16.00K
Free Cash Flow -$2.669M -$1.065M
YoY Change 7313.89% -36.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40073
dei Entity Registrant Name
EntityRegistrantName
SILEXION THERAPEUTICS CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Ha’ma’ayan Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Modi’in-Macabbim-Reut
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
7177871
dei City Area Code
CityAreaCode
+972
dei Local Phone Number
LocalPhoneNumber
8-6286005
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9768396 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1697000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4595000 usd
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
25000 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
25000 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
527000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
335000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
66000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
24000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
2315000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4979000 usd
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
25000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
25000 usd
CY2024Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
5000 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
5000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
140000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000 usd
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
210000 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
277000 usd
CY2024Q2 us-gaap Assets
Assets
2525000 usd
CY2023Q4 us-gaap Assets
Assets
5256000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
281000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
319000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
108000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
345000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
200000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
251000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
207000 usd
CY2024Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
1379000 usd
CY2023Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
1358000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2364000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2196000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59000 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
59000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
2372000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2255000 usd
CY2024Q2 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
15057000 usd
CY2023Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
15057000 usd
CY2024Q2 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
3353000 usd
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
3420000 usd
CY2024Q2 us-gaap Preferred Stock Redemption Amount
PreferredStockRedemptionAmount
18410000 usd
CY2023Q4 us-gaap Preferred Stock Redemption Amount
PreferredStockRedemptionAmount
18477000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3275000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3275000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
250492 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
250492 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
219354 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
219354 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11398000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11334000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29656000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-26811000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-18257000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-15476000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
153000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3001000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2525000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5256000 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
34000 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
34000 usd
CY2024Q2 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
17000 usd
CY2023Q2 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
17000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1727000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1916000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
766000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1235000 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
24000 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
24000 usd
CY2024Q2 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
12000 usd
CY2023Q2 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
12000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
908000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
306000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
619000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
179000 usd
us-gaap Operating Expenses
OperatingExpenses
2635000 usd
us-gaap Operating Expenses
OperatingExpenses
2222000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1385000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1414000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2635000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2222000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1385000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1414000 usd
slxn Financial Expenses Net From Related Party
FinancialExpensesNetFromRelatedParty
135000 usd
slxn Financial Expenses Net From Related Party
FinancialExpensesNetFromRelatedParty
0 usd
CY2024Q2 slxn Financial Expenses Net From Related Party
FinancialExpensesNetFromRelatedParty
60000 usd
CY2023Q2 slxn Financial Expenses Net From Related Party
FinancialExpensesNetFromRelatedParty
0 usd
slxn Financial Expenses
FinancialExpenses
270000 usd
slxn Financial Expenses
FinancialExpenses
377000 usd
CY2024Q2 slxn Financial Expenses
FinancialExpenses
102000 usd
CY2023Q2 slxn Financial Expenses
FinancialExpenses
452000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2905000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2599000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1487000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1866000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2912000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2619000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1489000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1876000 usd
us-gaap Profit Loss
ProfitLoss
-2845000 usd
us-gaap Profit Loss
ProfitLoss
-2427000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-1472000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-1653000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
67000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
192000 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
17000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
223000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2912000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2619000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1489000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1876000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
11.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.61
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.87
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.54
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
251655 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
252462 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
250847 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
252462 shares
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7567000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
412000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
64000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2619000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5424000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3001000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
64000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2912000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
153000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6856000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
412000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
32000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1876000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5424000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1610000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
32000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1489000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
153000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2912000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2619000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1489000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1876000 usd
us-gaap Depreciation
Depreciation
15000 usd
us-gaap Depreciation
Depreciation
29000 usd
CY2024Q2 us-gaap Depreciation
Depreciation
7000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
14000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
64000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
64000 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
32000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
32000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
219000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
257000 usd
CY2024Q2 us-gaap Other Noncash Expense
OtherNoncashExpense
83000 usd
CY2023Q2 us-gaap Other Noncash Expense
OtherNoncashExpense
278000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
192000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2000 usd
CY2024Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
63000 usd
CY2023Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5000 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
42000 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
9000 usd
CY2024Q2 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-2000 usd
CY2023Q2 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
20000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-38000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-57000 usd
CY2024Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
37000 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-52000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
4000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5000 usd
CY2024Q2 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2000 usd
CY2023Q2 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
44000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-62000 usd
CY2024Q2 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3000 usd
CY2023Q2 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-20000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
21000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-183000 usd
CY2024Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
327000 usd
CY2023Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-35000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2817000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2587000 usd
CY2024Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1065000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1676000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
507000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000 usd
CY2023Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
505000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
522000 usd
CY2023Q2 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
522000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
522000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
522000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2823000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1560000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1065000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1156000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-75000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-258000 usd
CY2024Q2 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-19000 usd
CY2023Q2 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-277000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4645000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8309000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2831000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7924000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1747000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6491000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1747000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6491000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1697000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6442000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1697000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6442000 usd
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
50000 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
49000 usd
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
50000 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
49000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1747000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6491000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1747000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6491000 usd
us-gaap Interest Paid Net
InterestPaidNet
25000 usd
us-gaap Interest Paid Net
InterestPaidNet
78000 usd
CY2024Q2 us-gaap Interest Paid Net
InterestPaidNet
6000 usd
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
39000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b>a.</b></td><td style="text-align: left">Silexion Therapeutics Ltd. (formerly known as Silenseed Ltd.) (hereinafter -“the Company”) was incorporated in Israel and began its operations on November 30, 2008. Since its incorporation, the Company has been engaged in one operating segment - the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming to stop the production of a specific pancreatic cancer-causing protein known as the KRAS mutation. The Company’s long-lived assets are located in Israel.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 0in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="text-align: left; width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b>b.</b></td><td style="text-align: left">On April 28, 2021, the Company signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (“GIBF”) to establish a new company in China. On June 15, 2021 a company was established in China, named Silenseed (China) Ltd (hereinafter - the “Subsidiary”). The Company owns 51% of the shares of the Subsidiary. The Subsidiary has not yet started significant operations as of June 30, 2024. The Company and the Subsidiary, together - “the Group”.</td> </tr></table> <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.7pt; text-indent: -28.45pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="text-align: left; width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b>c.</b></td><td style="text-align: left">On February 21, 2024, the Company entered into a business combination agreement with Moringa Acquisition Corp (the “SPAC”), a Cayman Islands exempted company whose class A ordinary shares (as well as other instruments) are listed for trade on the Nasdaq Capital Market (Nasdaq: MACA), and April M.G. Ltd. (the “April Merger Sub”), an Israeli company and a wholly-owned subsidiary of the SPAC (the “Original BCA”). According to the Original BCA, April Merger Sub was to merge with and into the Company, with the Company continuing as the surviving entity and a wholly-owned subsidiary of the SPAC, and with the SPAC continuing as a public company following the completion of the merger and with its securities continuing to be traded on Nasdaq.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 0in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="text-align: left; width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b>d.</b></td><td style="text-align: left">On April 3, 2024, the Company entered into an Amended and Restated Business Combination Agreement (hereinafter, “A&amp;R BCA”) with the SPAC, Biomotion Sciences, a newly-formed Cayman Islands exempted company (“Biomotion Sciences” or “New Pubco”), August M.S. Ltd. an Israeli company and wholly-owned subsidiary of Biomotion Sciences (“Merger Sub 1”), and Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and wholly-owned subsidiary of Biomotion Sciences (“Merger Sub 2”) which replaced the Original BCA. The A&amp;R BCA, provided for a technical change in the contemplated transaction structure to a “double dummy” structure, as a result of which both the Company and the SPAC will become wholly-owned subsidiaries of Biomotion Sciences, which will be the publicly-held, Nasdaq-listed entity, rather than the Company becoming a subsidiary of the Nasdaq-listed SPAC, as initially contemplated under the Original BCA.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: left; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">Pursuant to the transactions contemplated under the A&amp;R BCA (collectively, the “Business Combination “), Merger Sub 2 was to merge with and into the SPAC, with the SPAC continuing as the surviving company of such merger and a wholly-owned subsidiary of New Pubco (the “SPAC Merger”), and Merger Sub 1 was to merge with and into the Company, with the Company continuing as the surviving company of such merger and a wholly-owned subsidiary of New Pubco (the “Acquisition Merger”). Upon the effectiveness of the SPAC Merger, each outstanding SPAC Class A ordinary share and the sole outstanding SPAC Class B ordinary share was to convert into an ordinary share of New Pubco on a one-for-one basis. Each outstanding warrant to purchase one SPAC Class A ordinary share was to convert into a warrant to purchase one New Pubco ordinary share, at the same exercise price. Upon the effectiveness of the Acquisition Merger, each outstanding ordinary share and preferred share of the Company was to convert into such number of ordinary shares of New Pubco as is equal to the quotient obtained by dividing (x) the quotient obtained by dividing (1) $62,500 by (2) the number of fully diluted Company equity securities, by (y) $0.01 (the “Silexion Equity Exchange Ratio”). Each outstanding Company warrant and Company option to purchase one Company share, and Company restricted share unit (RSU) that may be potentially settled for one Company share, was to became exercisable for, or became subject to settlement for (as applicable), such number of New Pubco ordinary shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per New Pubco ordinary share of each such converted Company option and Company warrant was to be adjusted based on dividing the existing per share exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable, of such converted options, warrants and RSUs was to remain the same following such conversion, except that the vesting of each Company option was to accelerate immediately prior to the Acquisition Merger, such that the New Pubco option into which it was to be converted was to be fully vested, and all Company warrants were to be exercised (on a cashless basis) immediately prior to the Acquisition Merger. Immediately prior to the closing of the Business Combination, seven directors were to be elected to New Pubco’s board of directors, of whom five were to designated by the Company and two were to be designated by the SPAC’s sponsor (the “Sponsor”). The A&amp;R BCA also required, as a closing condition, the transfer of the remaining outstanding shares of the Subsidiary held by GIBF to the Company prior to the closing of the Business Combination in exchange for the issuance to GIBF of shares of the Company, which were to convert into ordinary shares of New Pubco in accordance with the Silexion Equity Exchange Ratio upon the closing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b>e.</b></td><td style="text-align: left">In connection with the closing of the Business Combination, the ordinary shares and warrants of Biomotion Sciences were expected to be listed on the Nasdaq Global Market and begin trading under the symbols “SLXN” and “SLXNW”, respectively.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b>f.</b></td><td style="text-align: left">The Business Combination was to be accounted for as a reverse recapitalization in accordance with US GAAP. Under this method of accounting, the Company was to be treated as the accounting acquirer and the SPAC was to be treated as the “acquired” company for financial reporting purposes. The Company was determined to be the accounting acquirer based on evaluation of the following facts and circumstances:</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.7pt; text-indent: -28.45pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the Company’s shareholders were to hold approximately 61.55% of the outstanding voting interests in New Pubco upon the closing of the Business Combination;</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the Company’s senior management were to comprise the senior management of New Pubco;</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the directors nominated by the Company were to constitute a majority of the board of directors of New Pubco (five out of seven of the initial directors);</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the Company’s operations were to comprise the ongoing operations of New Pubco; and</td> </tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the Company’s name was to be the name used by New Pubco (in replacement of Biomotion Sciences).</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-indent: -21.25pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">Under the reverse recapitalization accounting method, the Business Combination was to be deemed to be the equivalent of a capital transaction in which the Company will issue shares for the net assets of the SPAC. The net assets of the SPAC will be stated at fair value, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination will be those of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.7pt; text-indent: -28.45pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b>g.</b></td><td style="text-align: left">On June 18, 2024 the Company entered into a waiver with the other parties to the A&amp;R BCA (the “Investments Waiver”). The Investments Waiver provided, in principal part, that: (i) the conditions to closing under the A&amp;R BCA requiring that an equity financing of the Company in an amount of at least $3,500 (the “Silexion Equity Financing”) and an investment by the Sponsor in New Pubco of between $350 and $500 (the “Sponsor Investment”) shall have occurred, were waived; (ii) 1,382,325 of the Sponsor Investment shares that were potentially issuable to the Sponsor by New Pubco in respect of the Sponsor Investment under the A&amp;R BCA were to be issued to the Sponsor upon the closing notwithstanding that the Sponsor Investment has not taken place; (iii) the A&amp;R Sponsor Promissory Note Cap (which sets the maximum dollar amount of Sponsor loans to the SPAC that may be converted by the Sponsor into New Pubco ordinary shares, subject to reduction for certain fees payable at the Closing, under an amended and restated promissory note to be issued by New Pubco to the Sponsor at the closing (the “A&amp;R Sponsor Promissory Note”) was increased from $5.2 million to $5.5 million, and (iv) the controlling stakeholder of the Sponsor is to be entitled to a gross monthly fee of $10 for a period of 36 months following closing under the A&amp;R BCA. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></p> </td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b>h.</b></td><td style="text-align: left">On August 15, 2024, the Business Combination was completed (see Note 10).</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 0in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b>i.</b></td><td style="text-align: left">In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas and other terrorist organizations.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.7pt; text-indent: -28.45pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">The Company’s headquarters are located in Modiin, Israel. As of the issuance date of these consolidated financial statements, the conflict between Israel and Hamas has not had a material impact on the Company’s results of operations or financial position, if at all. The Company cannot currently predict the intensity or duration of Israel’s war against Hamas, however, as most of the Company’s trials are not executed in Israel, the Company does not believe the recent terrorist attack and the subsequent declaration of war by the Israeli government against the Hamas terrorist organization will have any material impact on its ongoing operations. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">Any hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners could adversely affect the Company’s operations and results of operations and could make it more difficult for the Company to raise capital.</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b>j.</b></td><td style="text-align: left"><b>Going concern:</b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in"><span>Since its inception, the Company has devoted substantially all its efforts to research and development, clinical trials, and capital raising activities. The Company is still in its development and clinical stage and has not yet generated revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in"><span>The</span> Company has incurred losses of $2,912 and $5,108 for the six-months period ended on June 30, 2024 and for the year ended December 31, 2023, respectively. <span>During the </span>six-month period ended <span>on June 30, 2024, the Company had negative operating cash flows of $2,817. As of June 30, 2024, the Company had cash and cash equivalents of $1,697. On August 15, 2024, the Company completed a business combination with the SPAC (see Note 10(f)).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in"><span>The Company expects to continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating various financing alternatives, as the Company will need to finance future research and development activities, general and administrative expenses and working capital through fund raising. However, there is no assurance that the Company will be successful in obtaining such funding. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in"><span>Under these circumstances, in accordance with the requirements of ASC 205-40, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern for at least 12 months from the date these financial statements are issued. The unaudited condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Debt And Equity Securities Gain Loss
DebtAndEquitySecuritiesGainLoss
62500000 usd
CY2024Q2 us-gaap Derivative Exchange Rate Cap1
DerivativeExchangeRateCap1
0.01 pure
CY2024Q2 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
1382325 shares
CY2024Q2 us-gaap Payments For Fees
PaymentsForFees
10000 usd
us-gaap Interest Costs Incurred
InterestCostsIncurred
2912000 usd
CY2023 us-gaap Interest Costs Incurred
InterestCostsIncurred
5108000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2817000 usd
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1697000 usd
us-gaap Use Of Estimates
UseOfEstimates
<b>Use of estimates</b><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. As applicable to these financial statements, the most significant estimates and assumptions relate share-based compensation and to fair value of financial instruments. See Note 6 and Notes 4 and 7, respectively. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</p>
us-gaap Operating Lease Payments
OperatingLeasePayments
25000 usd
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
25000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<b>Concentration of credit risks</b><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits. The Company deposits cash and cash equivalents mostly with three low risk financial institution. The Company has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.</p>
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
145000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-3000 usd
CY2024Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
64000 usd
CY2023Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-2000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3000 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3000 usd
us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-25000 usd
us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-78000 usd
CY2024Q2 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-6000 usd
CY2023Q2 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-39000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
148000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
451000 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
42000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
487000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
270000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
377000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
102000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
452000 usd
CY2022Q1 slxn Warrants Issued
WarrantsIssued
47495 shares
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
60.783
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
47495 shares
CY2023Q2 slxn Warrants Issued
WarrantsIssued
21717 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
24.769
CY2023Q2 us-gaap Other Expenses
OtherExpenses
3000 usd
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21717 shares
slxn Revaluation Expenses Income
RevaluationExpensesIncome
145000 usd
slxn Revaluation Expenses Income
RevaluationExpensesIncome
-3000 usd
CY2024Q2 slxn Revaluation Expenses Income
RevaluationExpensesIncome
64000 usd
CY2023Q2 slxn Revaluation Expenses Income
RevaluationExpensesIncome
-2000 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
64000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
64000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
39898 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
121808 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.23
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y10M17D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
31138 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.01
slxn Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term Exercised
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercised
P0Y3D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
490000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
735 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
26.78
slxn Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term Forfeited
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermForfeited
P6Y7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
30185 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
18.08
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
59750 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y4M2D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
33554 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
24.78
slxn Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term Exercisable
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercisable
P7Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
59750 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
25.66
slxn Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term Vested And Expected To Vest
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermVestedAndExpectedToVest
P7Y4M2D
us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
220000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y8M23D
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
64000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
64000 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32000 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
345000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
200000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7482 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.828 pure
us-gaap Net Income Loss
NetIncomeLoss
-2912000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2619000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1489000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1876000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2845000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2427000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1472000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1653000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
251655 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
252462 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
250847 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
252462 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
11.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.61
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.87
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.54
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
300 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
33108 shares
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
11.31
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.87
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.61
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
250847 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
251655 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
252462 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
252462 shares
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
usd
CY2024Q2 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
usd
CY2023Q2 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
usd
CY2024Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2024Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
CY2024Q2 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2024Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2023Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
CY2024Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
slxn Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term Granted
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermGranted
slxn Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term Expired
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExpired
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1472000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1653000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2427000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2845000 usd
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
250847 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
251655 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
252462 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
252462 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
11.31
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.87
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.61
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0002022416

Files In Submission

Name View Source Status
0001213900-24-073934-index-headers.html Edgar Link pending
0001213900-24-073934-index.html Edgar Link pending
0001213900-24-073934.txt Edgar Link pending
0001213900-24-073934-xbrl.zip Edgar Link pending
ea0212615-10q_silexion.htm Edgar Link pending
ea021261501ex31-1_silexion.htm Edgar Link pending
ea0212615-10q_silexion_htm.xml Edgar Link completed
ea021261501ex31-2_silexion.htm Edgar Link pending
ea021261501ex32-1_silexion.htm Edgar Link pending
ea021261501ex32-2_silexion.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slxn-20240630.xsd Edgar Link pending
slxn-20240630_def.xml Edgar Link unprocessable
slxn-20240630_lab.xml Edgar Link unprocessable
slxn-20240630_cal.xml Edgar Link unprocessable
slxn-20240630_pre.xml Edgar Link unprocessable